期刊文献+

纳米技术在乳腺癌治疗研究中的进展

Progress of nanotechnology on the treatment of breast cancer
原文传递
导出
摘要 近年来,纳米技术作为一项新的技术开拓了医学的新领域,为治疗很多疾病提供了新的方法。在乳腺癌治疗的研究中,发现纳米载体能很好地携带乳腺癌常用化疗药物,并能稳定释放药物。纳米材料在乳腺癌治疗方面有很好的靶向作用。在被动靶向方面,纳米载体能利用肿瘤微环境的改变提高增强渗透滞留效应,增加肿瘤局部药物浓度,进而提高抗乳腺癌效果;在主动靶向方面,乳腺癌分子靶向及磁性纳米微粒介导的靶向可提高乳腺癌细胞对抗癌药物的摄入。此外,纳米载体利用靶向效应部分逆转乳腺癌多药耐药,利用沉默相关耐药基因达到加强逆转的效果的作用。对于乳腺癌转移方面,纳米药物载体可以降低乳腺癌转移的风险,提高治疗乳腺癌骨转移的效果,对乳腺癌相关骨质疏松有一定的治疗效果。纳米技术在乳腺癌治疗中的应用前景越来越广阔。 In recent years, nanotechnology as a new technology expands the field of medicine, and provides a new method for the treatment of many diseases. For breast cancer, some studies found that nanoparticles used as carders could well carry conventional chemotherapy drugs and release drugs stably. Targeted therapy is an important application of nanomaterials in the treatment of breast cancer, including active and passive targeting. On passive targeting, nanoparticles can improve the enhanced permeability and retention effect and increase local drug concentration in tumor cells by changing the tumor microenvironments, so as to improve the effect of anti-breast cancer therapy. On active targeting, molecular targeting and magnetic nanoparticles mediated targeting can increase the uptake of anticancer drugs in breast cancer cells. In addition, nanoparticles can reverse the multi-drug resistance of breast cancer based on targeting effect and silencing related resistant genes. For the metastasis of breast cancer, nano-drug carrier can reduce the risk of breast cancer metastasis, improve effectiveness of treatment of bone metastasis in breast cancer and have a certain therapeutic effect on osteoporosis. The application prospect of nanoteclanology in the treatments of breast cancer will be wider and wider.
出处 《中华临床医师杂志(电子版)》 CAS 2015年第16期95-99,共5页 Chinese Journal of Clinicians(Electronic Edition)
关键词 纳米技术 乳腺癌 分子靶向治疗 载药系统 逆转耐药 骨转移 Nanotechnology Breast cancer Molecular targeted therapy Nano-drugcarrier Multidrug resistance Bone metastasis
  • 相关文献

参考文献38

  • 1Shalviri A,Raval G,Prasad P,et al.p H-Dependent doxorubicin release from terpolymer of starch,polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells[J].Eur J Pharm Biopharm,2012,82(3):587-597.
  • 2Murawala P,Tirmale A,Shiras A,et al.In situ synthesized BSA capped gold nanoparticles:Effective carrier of anticancer drug Methotrexate to MCF-7 breast cancer cells[J].Mater Sci Eng C Mater Biol Appl,2014,34:158-167.
  • 3Palma G,Conte C,Barbieri A,et al.Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer[J].Int J Pharm,2014,473(1/2):55-63.
  • 4Dai W,Jin W,Zhang J,et al.Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes[J].Pharm Res,2012,29(10):2902-2911.
  • 5Reynolds JG,Geretti E,Hendriks BS,et al.HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity[J].Toxicol Appl Pharmacol,2012,262(1):1-10.
  • 6Petros RA,De Simone JM.Strategies in the design of nanoparticles for therapeutic applications[J].Nat Rev Drug Discov,2010,9(8):615-627.
  • 7Fang J,Nakamura H,Maeda H.The EPR effect:Unique features of tumor blood vessels for drug delivery,factors involved,and limitations and augmentation of the effect[J].Adv Drug Deliv Rev,2011,63(3):136-151.
  • 8Bertrand N,Wu J,Xu X,et al.Cancer nanotechnology:the impact of passive and active targeting in the era of modern cancer biology[J].Adv Drug Deliv Rev,2014,66:2-25.
  • 9Yang L,Peng XH,Wang YA,et al.Receptor-targeted nanoparticles for in vivo imaging of breast cancer[J].Clin Cancer Res,2009,15(14):4722-4732.
  • 10Byrne JD,Betancourt T,Brannon-Peppas L.Active targeting schemes for nanoparticle systems in cancer therapeutics[J].Adv Drug Deliv Rev,2008,60(15):1615-1626.

二级参考文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部